Trump Claims ‘Perfect’ Score on Cognitive Test, Nvidia Deepens Healthcare AI Push
Former President Donald Trump stated today he “aced” a cognitive test, while tech giant Nvidia announced expanded partnerships aimed at revolutionizing drug discovery and healthcare through artificial intelligence.
Speaking to reporters, Trump, 79, claimed his performance on the Montreal Cognitive Assessment – a test commonly used to detect early signs of cognitive decline – surpassed that of younger Democratic women. “The first couple of questions are easy… but when you get up to 10 and 20 and 25, they couldn’t come close to answering any of those questions,” he said. He also asserted that a recent MRI scan was “perfect,” though provided no details regarding its purpose. This comes as concerns about the cognitive abilities of presidential candidates are increasingly scrutinized, as detailed in recent analyses of presidential health evaluations.
Meanwhile, Nvidia, which today reached a $5 trillion market capitalization, is significantly expanding its presence in the healthcare sector. A key collaboration involves Eli Lilly, with whom Nvidia will build an “AI factory” powered by over 1,000 Nvidia chips to accelerate drug development, automate manufacturing, and optimize clinical trials. Additional partnerships include Alphabet’s Verily, Johnson & Johnson, and Innovaccer, all integrating Nvidia’s AI technology into their respective platforms. These advancements could dramatically shorten the timeline and reduce the cost of bringing new therapies to market.
Beyond these partnerships, several significant deals are reshaping the biotech and pharmaceutical landscape: Novartis agreed to acquire Avidity Biosciences for $12 billion, and London-based GHO Capital secured $2.9 billion for a new healthcare fund. The FDA also approved expanding the label for Merck’s Winrevair, a potential blockbuster drug. Officials stated they will continue to monitor the impact of these developments on patient care and healthcare innovation.
